Acquisition of Exclusive Rights
On April 07, 2022, Centennial Growth Equities, Inc. signed with “VITAL FE” Joint Stock Company (“VITAL”) an Exclusive Rights Agreement for a term of 15 years for the production and distribution of Thymus Nuclear Glycoprotein (“TNG”). VITAL holds the technology to manufacture TNG and the intellectual property for Phase III Clinical Trial on TNG, started in 1997 and completed in 1998 in Infectious Diseases Hospital, Sofia on 20 patients suffering from AIDS in the advanced stages of the disease. The results of the clinical trial show that TNG has a significant place in the treatment of HIV. Under the terms of the agreement Centennial Growth Equities, Inc. has agreed to pay VITAL $80,000 or issue the equivalent number of Preferred Centennial Growth Equities, Inc. stock at a 0.01$ cost basis per share to a party elected by VITAL and VITAL has elected for 8,000,000 shares of Preferred Centennial Growth Equities, Inc. stock to be issued in the name of Dimitar Slavchev Savov. Dimitar Savov is Managing Director and owner of 70% stake in VITAL.
On April 07, 2022, Centennial Growth Equities, Inc. signed with “MICAR 11” LTD. (“MICAR”) an Exclusive Rights Agreement for a term of 15 years for the production and distribution of two dietary supplements, namely Palmcarotilen and Fiziolong. Palmcarotilen is a dietary supplement in the form of soft gelatin capsules that improves and regulates the metabolism of the epithelial cells and protects them from degenerative alterations. It favorably affects embryonic development; the regulation of the growth and division of the cells; stimulates the growth of the bone tissue; favorably affects the function of the gonads; increases and maintains high level of the immune system. Fiziolong is a dietary food supplement in the form of hard gelatin capsules, which serves as general stimulant for those in a period of convalescence, as well as in situations of high mental and physical loads, and for the recovery in sports. Under the terms of the agreement Centennial Growth Equities, Inc. has agreed to pay MICAR $20,000 or issue the equivalent number of Preferred Centennial Growth Equities, Inc. stock at a 0.01$ cost basis per share to a party elected by MICAR and MICAR has elected for 2,000,000 shares of Preferred Centennial Growth Equities, Inc. stock to be issued in the name of Dimitar Slavchev Savov. MICAR is wholly owned by Dimitar Savov and he acts as its Managing Director.
As of April 11, 2022 and due to the acquisition detailed in the previous paragraphs and updated business scope, Centennial Growth Equities, Inc. is no longer designated as a shell company.
See the full 8K Report at sec.report.